GlassScriptPhysician profile
Edward M Stafford
NPI 1356499081
$665.44
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.62 · 2020: $55.46 · 2021: $26.39 · 2022: $43.23 · 2023: $254 · 2024: $119 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.27 |
| Education | $164.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $249.15 | 2020-2024 | Dupixent |
| Cochlear Americas | $175.28 | 2019-2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Glaxosmithkline, LLC. | $40.63 | 2025 | Nucala |
| Genzyme Corporation | $39.61 | 2024-2025 | |
| Aerin Medical INC. | $28.71 | 2019-2023 | |
| Acclarent, INC | $28.65 | 2021-2022 | |
| Amgen INC. | $21.90 | 2025 | Tezspire |
| Medtronic, INC. | $18.19 | 2024 | Pteye Parathyroid Detection System |
| Ars Pharmaceuticals Operations, INC. | $17.59 | 2025 | Neffy |
| Phathom Pharmaceuticals, INC. | $17.43 | 2025 | Voquezna |
| Karl Storz Endoscopy-America | $16.55 | 2024 | |
| Smith+Nephew, INC. | $11.75 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$53,346.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.